NCT03856242 is a Phase 4 clinical trial of Tamsulosin Oral Capsule in Ischaemic Heart Disease (IHD), sponsored by I.M. Sechenov First Moscow State Medical University.

Who is sponsoring NCT03856242?

NCT03856242 is sponsored by I.M. Sechenov First Moscow State Medical University.

What drugs are being tested in NCT03856242?

Interventions in NCT03856242: Tamsulosin Oral Capsule, TURP.

What condition does NCT03856242 study?

NCT03856242 studies Ischaemic Heart Disease (IHD), Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS).

Is NCT03856242 still recruiting?

NCT03856242 is currently completed. Last updated 27 February 2019.

Last reviewed 2019-02-27 · How we verify

NCT03856242

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Benign Prostatic Hyperplasia and Ischemic Heart DIsease

Completed Phase 4 Last updated 27 February 2019

What this trial tests

Phase 4 trial testing Tamsulosin Oral Capsule in Ischaemic Heart Disease (IHD) in 83 participants. Completed in 1 September 2017.

Timeline

1 September 2015

Primary endpoint
1 September 2017

1 September 2017

Quick facts

Lead sponsor	I.M. Sechenov First Moscow State Medical University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	83
Start date	1 September 2015
Primary completion	1 September 2017
Estimated completion	1 September 2017

Drugs / interventions tested

Tamsulosin Oral Capsule
TURP

Conditions studied

Ischaemic Heart Disease (IHD) — all drugs for Ischaemic Heart Disease (IHD) →
Benign Prostatic Hyperplasia (BPH) — all drugs for Benign Prostatic Hyperplasia (BPH) →
Lower Urinary Tract Symptoms (LUTS) — all drugs for Lower Urinary Tract Symptoms (LUTS) →

Sponsor

I.M. Sechenov First Moscow State Medical University

Who can join

Adults 57 to 81, male only, with Ischaemic Heart Disease (IHD) or Benign Prostatic Hyperplasia (BPH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To examine the dynamics of 24 - hours ECG monitoring parameters (Holter monitoring) in patients with ischaemic heart disease (IHD) before and after treatment of voiding dysfunctions resulted from benign prostatic hyperplasia (BPH) with the indications for either conservative or operative treatment. A total of eighty-three 57-to-81-year-old (mean age 70.4±5.75 years) patients with BPH and accompanying IHD were examined at the Institute of Urology and Human Reproductive Health and Clinic of Cardiology of the Sechenov University.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Holter Monitoring (24-Hour ECG) Parameter Dynamics in Patients with Ischemic Heart Disease and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Fiev DN, Vinarov AZ, Tsarichenko DG, Kopylov PY, et al · · 2019 · cited 2× · PMID 31148056 · DOI 10.1007/s12325-019-00977-8

Verify or expand the search:

Other trials of Tamsulosin Oral Capsule

Trials testing the same drug.

NCT05977647 — Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi · Phase 4 · completed
NCT04557202 — Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones: A · Phase 3 · completed

Other I.M. Sechenov First Moscow State Medical University trials

Trials by the same sponsor.

NCT07348991 — Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG · not yet recruiting
NCT07412457 — Guideline Adherence in Dyslipidemia With Clinical Decision Support · not yet recruiting
NCT07396792 — Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram · not yet recruiting
NCT07412418 — Screening for Pulmonary Embolism Using Single-channel Electrocardiogram · not yet recruiting
NCT07518550 — Maternal and Fetal Electrocardiograms Separation Algorithm · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03856242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by I.M. Sechenov First Moscow State Medical University
Last refreshed: 27 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03856242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing